“Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 1, no. 3.1, p. s23, Oct. 2017, doi: 10.25251/skin.1.supp.22.